+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bioengineered Protein Drugs Market - Global Forecast 2026-2032- Product Image
Bioengineered Protein Drugs Market - Global Forecast 2026-2032- Product Image
New

Bioengineered Protein Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 196 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011369
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The bioengineered protein drugs market is entering a period of accelerated innovation, driven by scientific progress and evolving regulatory requirements. Senior decision-makers face increased complexity in balancing therapeutic development, operational strategy, and region-specific considerations within this rapidly advancing sector. Understanding the interplay of these factors is essential for securing a lasting competitive edge in the bioengineered protein therapeutics landscape.

Market Snapshot: Bioengineered Protein Therapeutics

The Bioengineered Protein Drugs Market expanded from USD 448.38 billion in 2025 to USD 484.29 billion in 2026 and is projected to reach USD 772.19 billion by 2032, based on a CAGR of 8.07%. This growth reflects strong demand for next-generation biologic treatments across diverse therapeutic areas. Trends such as increased adoption of advanced manufacturing technologies and heightened focus on quality and scalability are shaping the industry’s upward trajectory. Market participants must respond to regional demands, evolving payer expectations, and persistent supply chain challenges to capture future growth opportunities.

Scope & Segmentation

  • Drug Class: Enzymes, fusion proteins, monoclonal antibodies, PEGylated proteins, and recombinant proteins—such as erythropoietins, growth factors, insulins, and interferons—each present unique complexities for development, formulation, and analytics.
  • Therapeutic Indications: Focus spans endocrinology, hematology, immunology, infectious diseases, and oncology, with distinct requirements for chronic disease management, precision in potency, and adaptable combination strategies.
  • Route of Administration: Includes intramuscular, intravenous, and subcutaneous delivery, influencing formulation science, device integration, and overall patient experience.
  • End User Settings: Hospitals, clinics, and home care environments each drive specific needs for drug packaging, product stability, and tailored delivery support services for improved patient access.
  • Platform Technologies: Mammalian cell systems (including CHO and NS0 lines), microbial expression options (E. coli, yeast), and transgenic hosts (animal and plant-based) contribute to product quality, production flexibility, and risk management profiles.
  • Regions: Americas, Europe Middle East and Africa, and Asia-Pacific introduce a range of clinical, regulatory, and commercial considerations that influence market entry, supply chain resilience, and strategic localization initiatives.

Key Takeaways: Strategic Insights for Decision Makers

  • The increasing scientific and regulatory complexity of bioengineered protein therapeutics demands strategic integration of R&D, manufacturing, and market access functions for effective commercialization.
  • Advances in next-generation protein constructs provide differentiated therapeutic options, addressing new indications and supporting lifecycle management strategies to extend market relevance.
  • Operational resilience has gained importance, as stakeholders prioritize value-based outcomes and cost control, requiring more effective management of patient adherence and comparative effectiveness measures.
  • Cross-functional collaboration is essential, with organizations leveraging strategic partnerships—such as with CDMOs, technology providers, and academic consortia—to accelerate innovation and close internal capability gaps.
  • Segment-specific approaches are necessary to align product design and delivery with diverse clinical and payer expectations, optimizing value across the entire product pipeline.
  • Regional heterogeneity necessitates customized market entry, supply chain, and commercialization strategies to ensure broad patient access and reliable delivery even in volatile policy environments.

Tariff Impact: Trade Policy Effects

The introduction of United States tariffs in 2025 generated new challenges for sourcing inputs, controlling logistics, and stabilizing costs across global bioengineered protein drug manufacturing. Industry responses included redesigning supply chains, qualifying new material providers, and shifting toward regionalization to offset cost fluctuations and minimize risk exposure. Contract manufacturers reflected tariff compliance in their pricing while pharmaceutical companies intensified negotiations with payers and adapted internal processes for efficiency. These actions underscore the necessity for integrated supply-chain and commercial risk planning to support consistent patient access amid ongoing trade policy shifts.

Methodology & Data Sources

This report employs robust data triangulation utilizing peer-reviewed literature, official disclosures, regulatory filings, and interviews with industry experts. Senior bioprocess scientists and regulatory authorities validated key findings, with cross-verification steps ensuring the objectivity and credibility of recommendations. Transparent, non-proprietary methodologies were used throughout the analysis.

Why This Report Matters

  • Enables evidence-based decisions by linking detailed segmentation and regional analysis to market and product development opportunities.
  • Offers actionable guidance for optimizing drug pipelines, managing risk, and aligning regulatory strategies to shifting market needs.
  • Prepares leaders to adapt efficiently to changes in regulatory and policy landscapes, fostering organizational resilience and robust supply chains.

Conclusion

Effective market leadership depends on integrating scientific, regulatory, and commercial strategies with agile planning and strong cross-functional collaboration. Success in the evolving bioengineered protein drugs sector relies on operational excellence, responsive partnerships, and proactive adaptation to regulatory and policy developments.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Bioengineered Protein Drugs Market, by Drug Class
8.1. Enzymes
8.1.1. Alglucosidase
8.1.2. Asparaginase
8.2. Fusion Proteins
8.3. Monoclonal Antibodies
8.3.1. Chimeric
8.3.2. Fully Human
8.3.3. Humanized
8.3.4. Murine
8.4. PEGylated Proteins
8.4.1. PEGylated Interferon
8.4.2. PEGylated Therapies
8.5. Recombinant Proteins
8.5.1. Erythropoietin
8.5.2. Growth Factors
8.5.2.1. G-CSF
8.5.2.2. GM-CSF
8.5.2.3. PDGF
8.5.3. Insulin
8.5.3.1. Intermediate Acting
8.5.3.2. Long Acting
8.5.3.3. Rapid Acting
8.5.4. Interferons
8.5.4.1. Alpha
8.5.4.2. Beta
8.5.4.3. Gamma
9. Bioengineered Protein Drugs Market, by Therapeutic Indication
9.1. Endocrinology
9.1.1. Diabetes Mellitus
9.1.2. Growth Disorders
9.2. Hematology
9.2.1. Anemia
9.2.2. Bleeding Disorders
9.3. Immunology
9.3.1. Inflammatory Bowel Disease
9.3.2. Psoriasis
9.3.3. Rheumatoid Arthritis
9.4. Infectious Diseases
9.4.1. Bacterial Infections
9.4.2. Viral Infections
9.5. Oncology
9.5.1. Hematological Malignancies
9.5.2. Solid Tumors
10. Bioengineered Protein Drugs Market, by Technology Platform
10.1. Mammalian Cell Expression
10.2. Microbial Expression
10.2.1. E. coli
10.2.2. Yeast
10.3. Transgenic Host Expression
10.3.1. Animal Based
10.3.2. Plant Based
11. Bioengineered Protein Drugs Market, by Route of Administration
11.1. Intramuscular
11.2. Intravenous
11.3. Subcutaneous
12. Bioengineered Protein Drugs Market, by End User
12.1. Clinic
12.2. Home Care
12.3. Hospital
13. Bioengineered Protein Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Bioengineered Protein Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Bioengineered Protein Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Bioengineered Protein Drugs Market
17. China Bioengineered Protein Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. Amgen Inc.
18.7. Bristol-Myers Squibb Company
18.8. Eli Lilly and Company
18.9. F. Hoffmann-La Roche Ltd
18.10. Johnson & Johnson
18.11. Merck & Co., Inc.
18.12. Novartis AG
18.13. NOVO NORDISK A/S
18.14. Pfizer Inc.
18.15. Sanofi S.A.
List of Figures
FIGURE 1. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALGLUCOSIDASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALGLUCOSIDASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALGLUCOSIDASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ASPARAGINASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ASPARAGINASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ASPARAGINASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MURINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MURINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED INTERFERON, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED INTERFERON, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED INTERFERON, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY G-CSF, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY G-CSF, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY G-CSF, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GM-CSF, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GM-CSF, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GM-CSF, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PDGF, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PDGF, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PDGF, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERMEDIATE ACTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERMEDIATE ACTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERMEDIATE ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY LONG ACTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY LONG ACTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY LONG ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RAPID ACTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RAPID ACTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RAPID ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GAMMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GAMMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GAMMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES MELLITUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES MELLITUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLEEDING DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLEEDING DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLEEDING DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY E. COLI, BY REGION, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY E. COLI, BY GROUP, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY E. COLI, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY YEAST, BY REGION, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY YEAST, BY GROUP, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, 2018-2032 (USD MILLION)
TABLE 160. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANIMAL BASED, BY REGION, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANIMAL BASED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANIMAL BASED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PLANT BASED, BY REGION, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PLANT BASED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PLANT BASED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 168. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 169. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 171. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 172. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 174. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 175. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 176. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 178. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 179. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 181. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 184. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 185. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 186. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 187. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 188. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 189. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
TABLE 190. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 191. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2018-2032 (USD MILLION)
TABLE 192. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 193. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
TABLE 194. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 195. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2018-2032 (USD MILLION)
TABLE 196. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 197. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
TABLE 198. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
TABLE 199. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
TABLE 200. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 201. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 202. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 203. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, 2018-2032 (USD MILLION)
TABLE 204. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, 2018-2032 (USD MILLION)
TABLE 205. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 206. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 207. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 209. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
TABLE 210. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 211. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2018-2032 (USD MILLION)
TABLE 212. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 213. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
TABLE 214. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 215. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2018-2032 (USD MILLION)
TABLE 216. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 217. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
TABLE 218. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
TABLE 219. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
TABLE 220. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 221. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 222. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 223. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, 2018-2032 (USD MILLION)
TABLE 224. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, 2018-2032 (USD MILLION)
TABLE 225. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 226. NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 227. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 228. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 229. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
TABLE 230. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 231. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2018-2032 (USD MILLION)
TABLE 232. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 233. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
TABLE 234. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 235. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2018-2032 (USD MILLION)
TABLE 236. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 237. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
TABLE 238. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
TABLE 239. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
TABLE 240. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 241. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 242. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 243. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, 2018-2032 (USD MILLION)
TABLE 244. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, 2018-2032 (USD MILLION)
TABLE 245. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 246. LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2018-2032 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2018-2032 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, 2018-2032 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, 2018-2032 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 267. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 268. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 269. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
TABLE 270. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 271. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2018-2032 (USD MILLION)
TABLE 272. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 273. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
TABLE 274. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 275. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2018-2032 (USD MILLION)
TABLE 276. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 277. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
TABLE 278. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
TABLE 279. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
TABLE 280. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 281. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 282. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 283. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, 2018-2032 (USD MILLION)
TABLE 284. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, 2018-2032 (USD MILLION)
TABLE 285. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 286. EUROPE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 287. MIDDLE EAST BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 288. MIDDLE EAST BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 289. MIDDLE EAST BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
TABLE 290. MIDDLE EAST BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 291. MIDDLE EAST BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2018-2032 (USD MILLION)
TABLE 292. MIDDLE EAST BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 293. MIDDLE EAST BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
TABLE 294. MIDDLE EAST BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 295. MIDDLE EAST BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2018-2032 (USD MILLION)
TABLE 296. MIDDLE EAST BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 297. MIDDLE EAST BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
TABLE 298. MIDDLE EAST BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2

Companies Mentioned

The key companies profiled in this Bioengineered Protein Drugs market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • NOVO NORDISK A/S
  • Pfizer Inc.
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages196
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 484.29 Billion
Forecasted Market Value ( USD ) by 2032 $ 772.19 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Bioengineered Protein Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Bioengineered Protein Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Bioengineered Protein Drugs: Market Share, and Growth Analysis by Product Type (Monoclonal Antibodies, Recombinant Proteins, Fusion Proteins), Application, End User, Technology - Product Image

Bioengineered Protein Drugs: Market Share, and Growth Analysis by Product Type (Monoclonal Antibodies, Recombinant Proteins, Fusion Proteins), Application, End User, Technology

  • Report
  • 150 Pages
  • Global
From
Bioengineered Protein Drugs Market Report 2025 - Product Image

Bioengineered Protein Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Bioengineered Protein Drugs - Global Strategic Business Report - Product Image

Bioengineered Protein Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Protein Therapeutics Market - Global Forecast 2026-2032 - Product Image

Protein Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.